

Important Safety Information for Patient Receiving TECVAYLI® ▼ (teclistamab) Patient Card

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

TECVAYLI® is used to treat a cancer of the bone marrow called multiple myeloma and for patients who have at least three other kinds of treatments that have not worked or stopped working.¹

Carry this card with you at all times. **SHOW THIS CARD** to any healthcare professional involved in your care and if you go to the hospital.

FOLD HERE

This card provides information about cytokine release syndrome (CRS).

TECVAYLI® can cause side effects such as CRS.

CRS is a serious immune reaction that can be triggered by a variety of factors, including certain drugs.

PATIENT'S NAME:

Emergency Contact

PATIENT CARER'S NAME:

**PATIENT CARER'S
PHONE NUMBER:**

FOLD HERE

Important Information for Patients

Get medical help straight away if you experience any of the following:¹

- Fever (38°C or higher)
- Chills
- Fast heartbeat
- Difficulty breathing
- Nausea
- Headache
- Feeling dizzy

FOLD HERE

Important to Remember

Stay close to the location where you received your TECVAYLI® therapy for at least two days for daily monitoring after administration of your first three doses (usually two step-up doses and first maintenance dose).¹

If you have any of the symptoms listed on this card call your doctor or seek emergency medical attention right away! These are not all the possible side effects of TECVAYLI®. Tell your doctor if you have any side effect that bothers you or does not resolve.

Treating Physician

TREATING PHYSICIAN'S
NAME:

TREATING PHYSICIAN'S
PHONE NUMBER:

HOSPITAL NAME AND
ADDRESS:

HOSPITAL PHONE NUMBER:

FOLD HERE

Information for Healthcare Team to Fill In

Please give this card to your healthcare team to fill in the information and return to you.

Dates of TECVAYLI® injections (step-up dosing schedule):

STEP-UP DOSE 1 _____

STEP-UP DOSE 2 _____

FIRST MAINTENANCE DOSE* _____

*This is the first full treatment dose (1.5 mg/kg)¹

FOLD HERE

Important Safety Information for Healthcare Professionals

CRS, including life-threatening or fatal reactions, may occur in patients receiving TECVAYLI®.¹ CRS may involve multiple organ systems. Assess the patient for signs and symptoms of CRS. If your patient reports any signs or symptoms as referenced on this card, please contact the patient's treating physician immediately for further information.

See Summary of Product Characteristics for full details.¹

FOLD HERE

Reporting of Side Effects

If you get side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in the Patient Information Leaflet. You can also report side effects directly via the national reporting system: Yellow Card Scheme (<https://yellowcard.mhra.gov.uk/> or search for MHRA Yellow Card in the Google Play or Apple App Store). Alternatively, you can call 0800 731 6789 for free, Monday to Friday between 9:00am and 5:00pm. Any adverse reactions to TECVAYLI should be reported to Janssen via email (dsafety@its.jnj.com) or by telephone (01494 567447).

1. TECVAYLI® (teclistamab) Summary of Product Characteristics (10 mg/mL and 90 mg/mL solutions). Available from: <https://www.medicines.org.uk/emc/search?q=tecvayli>.